Managing the known unknowns: Theranostic cancer nanomedicine and informed consent

Methods in Molecular Biology

Volumn 726, Issue , 2011, Pages 413-429

  Jotterand, Fabrice ^a   Alexander, Archie A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer; Ethics; Informed consent; Nanomedicine; Policy; Risk management; Theranostics

Indexed keywords

ARTICLE; ETHICS; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; NANOMEDICINE; NEOPLASM; RISK MANAGEMENT;

COMMUNICATION; HUMANS; INFORMED CONSENT; NANOMEDICINE; NEOPLASMS; RISK MANAGEMENT;

EID: 79959811282     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-052-2_26     Document Type: Chapter

References (56)

1. Abel, J. “Nanomedicine and Cancer” Available online: Http://www.chem.usu.edu/~tapaskar/Joe-Seminar-Nano-Medicine.pdf.
2. European Science Foundation Nanomedicine Report (2005) Available online: Http://www.esf.org/publication/214/Nanomedicine.pdf.
3. Sumer, B. and Gao, J. (2008) Theranostic nanomedicine for cancer. Nanomedicine 3, 137-140.
4. Muthu, M. and Singh, S. (2009) Targeted nanomedicine: Effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine 4, 105-118.
5. Tassinari, O., Caiazzo R. J., Ehrlich J. R., and Liu, B.C-S. (2008) Identifying autoantigens as theranostic targets: Antigen arrays and immunoproteonics approaches. Curr. Opin. Mol. Ther. 10, 107-115.
6. Del Vecchio, S., Zannetti, A., Fonti, R., Pace, L., and Salvatore, M. (2007) Nuclear imaging in cancer theranostics. Q. J. Nucl. Med. Mol. Imag. 51, 152-163.
7. Ramachandran, G. (June 26, 2009) Theranostics: An evolving field catering to the unmet needs of the medical world. http:// www.frost.com/prod/servlet/market-insightprint.pag?docid=170968864. Accessed 28 October 2009.
8. Visogain. (May 29, 2009) In vitro diagnostics: Market analysis 2009-2024. http://www.prlog.org/10246394-in-vitro-diagnosticsmarket-analysis-20092024.pdf. Accessed 28 October 2009.
9. Blair, E. D. (2008) Assessing the value-adding impact of diagnostic-type tests on drug development and marketing. Mol. Diag. Ther. 12, 331-337.
10. Jotterand, F. (2007) Nanomedicine: How it could reshape clinical practice. Nanomedicine 2, 401-405.
11. th June 2007.
12. Girod, J. and Klien, A. R. (2009) Predictive health technologies: Personalized medicine and toxic exposures. Hous. J. Health L. Policy 9, 163-178.
13. Wilson, R. F. (2006) Symposium article: Nanotechnology: The challenge of regulating known unknowns. J. Law Med. Ethics 34, 704-713.
14. Rakhlin, M. (2008) Regulating nanotechnology: A private-public insurance solution. Duke Law Tech. Rev. 2008, 2-45.
15. Resnick, B. R. and Tinkle, S. S. (2007) Ethical issues in clinical trials involving nanomedicine. Contemp. Clin. Trials. 28, 433-441.
16. Bawa, R. and Johnson, S. (2007) The ethical Dimensions of nanomedicine. Med. Clin. N. Ann. 91, 881-887.
17. Wolinski, H. (2006) Nanoregulation. EMBO Rep. 7, 858-861.
18. Katz, J. (2009) Informed consent-Must it remain a fairy tale? in: Ethical Issues in Modern Medicine (7th edition) (Steinbock, B. Arras, J. D., and London, A. J., eds.) McGraw Hill, New York.
19. Furrow, B. R., Greaney, T. L., Johnson, S. H., Jost, T. S., and Schwartz, R. L. (2000) Health Law (2nd edition). Hornbook series, West Group, West Publishing Co.
20. Grim, D. A. (2007) Informed consent for all! No exceptions. New Mexico L. Rev.37, 39-83.
21. Etchells, E. (1999) Informed consent in surgical trials. World J. Surg. 23, 1215-1220.
22. Jotterand, F., McClintock, S. M., Alexander, A. A., and Husain, M. M. (2010) Ethics and informed consent of Vagus Nerve Stimulation (VNS) for patients with Treatment-Resistant Depression (TRD). NeuroEthics 3, 13-22.
23. Beauchamp, T. L. and Childress, J. F. (2009). Principles of Biomedical Ethics (6th edition). Oxford University Press, Oxford.
24. Brock, D. (1987). Informed consent. in: Health Care Ethics (Van De Veer, D. and Regan T., eds.) Temple University Press, Philadelphia.
25. Virdi, J. (2008) Bridging the knowledge gap: Examining potential limits in nanomedicine. Spon. Gen. 2, 25-44.
26. Breggin, L., Falkner, R., Jaspers, N., Pendergrass, J., and Porter, R. (2009) Securing the promise of nanotechnologies. Chatham House, London, England: Regulating Nanotechnologies in the EU and US. http://www.lse.ac.uk/internationalRelations/centresandunits/regulatingnanotechnologies/nanopdfs/REPORT.pdf. Assessed 29 October 2009.
27. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) (2009) Risk Assessment of Products of Nanotechnologies. http://ec.europa.eu/health/ph_risk/committees04_scenihr_o_023.pdf. Accessed 28 October 2009.
28. Nanotechnology: A report of the U.S. Food and Drug Administration. Rockville, Maryland: Nanotechnology Task Force (2007). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/Nanotechnology/ucm110856.pdf. Accessed 10 October 2009.
29. Pelley, J. and Saner, M. (2009) International approaches to the regulatory governance of nanotechnology. Ottawa, Ontario: Regulatory Governance Initiative. http://www.carleton.ca/regulation/publications/Nanotechnology_Regulation_Paper_April2009.pdf. Assessed 20 September 2009.
30. Greenpeace: policy and position paper on Nanotechnology (2002) http://www.greenpeace.org/raw/content/denmark/press/apporter-or-dokumenter/nanotechnology-policy-positi.pdf. Accessed on 1 October 2009.
31. Tyshenko, M. G. and Krewski, D. (2008) A risk management framework for the regulation of nanomaterials. Int. J. Nanotechnol. 5, 143-160.
32. Renn, O. and Roco, M.C. (2006) Nanotechnology and the need for risk governance. J. Nanopart. Res. 8, 153-191.
33. Jardine, C. G., Hrudey, S. E., Shortreed, J. H., Craig, L., Krewski, D., Furgal, C., et al. (2003) Risk management frameworks for human health and environmental risks. J. Toxicol. Environ. Health, Part B 6, 570-718.
34. Maynard, A. D. (2006) Nanotechnology: Assessing the risks. Nanotoday 1, 22-32.
35. Patra, D., Ejnavarzala, H. and Basu, P. K. (2009) Nanoscience and nanotechnology: Ethical, legal, social and environmental issues. Curr. Sci. 96, 651-657.
36. Orberdorster, G., Oberdorster, E., and Oberdorster, J. (2005) Nanotechnology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 623-839.
37. Azou, B. L., Jorly, J., On, D., Sellier, E., Moisan, F., Fleury-Feith, J., et al. (2008) In vitro effects of nanoparticles on renal cells. Part. Fibre Tox. 5, 22.
38. Song, Y., Li, X. and Du, X. (2009) Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur. Respir. J. 34, 559-567.
39. Marchant, G. E., Sylvester, D. J., and Abbott, K. W. (2008) Risk management principles for nanotechnology. Nanoethics 2, 43-60.
40. Linkov, I., Steevens, J., Adlakha-Hutcheon, G., Bennett, E., Chappell, M., Colvin, V., et al. (2009) Emerging methods and tools for environment risk assessment, decision-making, and policy for nanomaterials: Summary of NATO Advance Research Workshop. J. Nanopart. Res. 11, 513-527.
41. Linkov, I., Satterstrom, F. K., Steevens, J., Ferguson, E., and Pleus, R. C. (2007) Multicriteria analysis environmental risk assessment for nanomaterials. J. Nanopart. Res. 9, 543-554.
42. Farber, D. and Lakhtakia, A. (2009) Scenario planning and nanotechnologies futures. Eur. J. Phys. 30, S3-S15.
43. Kuzma, J., Paradise, J., Ramachandran, G., Kim, J.-A., Kokotovich, A., and Wolk, S. M. (2008) An integrated approach to oversight assessment for emerging technologies. Risk Anal. 28, 1197-1219.
44. Nano Risk Framework, Washington D.C. and Wilmington, Delaware: Environmental Defense-DuPont Nano Partnership (2007) http://www.edf.org/documents/6496_Nano%20Risk%20Framework.pdf. Accessed on 20 October 2009.
45. Bowman, D. M. and Hodge, G. A., (2007) A small matter of regulation: An international review of nanotechnology regulation. Columbia Sci. Tech. L. Rev. 8, 1-36.
46. Bowman, D. M. and Hodge, G. A. (2006) Nanotechnology: Mapping the wild regulatory frontier. Futures 38, 1060-1073.
47. Vines, T. and Faunce, T. (2009) Assessing the safety and cost-effectiveness of early nanodrugs. J. Law Med. 16, 822-45.
48. Till, M. C., Simkin, M. M. and Maebius, S. (2005) Nanotech meets the FDA: A success story about the nanoparticle drugs approved by the FDA. Nanotechnology Law & Bus. 2.2, 163-167.
49. Faunce, T. A. (2008) Toxicological and public good considerations for the regulation of nanomaterial-containing medical products. Expert Opin. Drug Saf. 7, 103-106.
50. U.S. National Institutes of Health, Nanoparticle Studies. [Clinical Trials.gov] http://www.clinicaltrails.gov/ct2/results?term=nano. Accessed on Nov. 10, 2009.
51. Beasley, J. C., Kramer, V. L., and Priest, S. H. (2008) Expert opinion on nanotechnology: Risks, benefits, and regulation. J. Nanopart. Res. 10, 549-558.
52. Weijer, C. and Miller, P. B. (2004) When are research risks reasonable in relation to anticipated benefits? Nat. Med. 10, 570-573.
53. Wendler, D. and Miller, F. G. (2004) Assessing research risks systematically: The net risks test. J. Med. Ethics 33, 481-486.
54. Avom, J. (2006) Dangerous deception-hiding the evidence of adverse drug effects. NEJM 355, 2170-2171.
55. King, S. K. and Moulton, B. W. (2006) Rethinking informed consent: The case for shared medical decision making. Am. J. Law Med. 32, 429-493.
56. Plows, A. and Reinsborough, M. (2008) Nanobiotechnology and Ethics: Converging Civil Society Discourses. in: Emerging Conceptual, Ethical and Policy Issues in Bionanotechnology (Jotterand, F., ed.) Dordrecht, Springer.